| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
CAR T in adult ALL: When and for whom?
|
Connor, Matthew P.
|
|
|
34 |
1 |
p.
|
artikel
|
| 2 |
Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia
|
Hasserjian, Robert P.
|
|
|
34 |
1 |
p.
|
artikel
|
| 3 |
Editorial Board / Aims & Scope
|
|
|
|
34 |
1 |
p.
|
artikel
|
| 4 |
Have any strategies in Ph-like ALL been shown to be effective?
|
Aldoss, Ibrahim
|
|
|
34 |
1 |
p.
|
artikel
|
| 5 |
How old is too old for a transplant?
|
Weisdorf, Daniel
|
|
|
34 |
1 |
p.
|
artikel
|
| 6 |
Hypomethylating agents as maintenance therapy following allogeneic hematopoietic cell transplantation for myeloid malignancies
|
Appelbaum, Frederick R.
|
|
|
34 |
1 |
p.
|
artikel
|
| 7 |
Immune checkpoint inhibitors in acute myeloid leukemia
|
Daver, Naval
|
|
|
34 |
1 |
p.
|
artikel
|
| 8 |
Index
|
|
|
|
34 |
1 |
p.
|
artikel
|
| 9 |
Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?
|
Levis, Mark
|
|
|
34 |
1 |
p.
|
artikel
|
| 10 |
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
|
Bewersdorf, Jan Philipp
|
|
|
34 |
1 |
p.
|
artikel
|
| 11 |
Managing older adults with Ph-negative ALL: What is new? Recent advances in treating older adults with ALL
|
Park, Jae H.
|
|
|
34 |
1 |
p.
|
artikel
|
| 12 |
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax
|
Konopleva, Marina Y.
|
|
|
34 |
1 |
p.
|
artikel
|
| 13 |
Molecular alterations governing predisposition to myelodysplastic syndromes: Insights from Shwachman-Diamond syndrome
|
Shimamura, Akiko
|
|
|
34 |
1 |
p.
|
artikel
|
| 14 |
Novel therapeutic targets for chronic myelomonocytic leukemia
|
Lasho, Terra
|
|
|
34 |
1 |
p.
|
artikel
|
| 15 |
Overcoming graft failure after haploidentical transplantation: Is this a possibility?
|
Huang, Xiao-Jun
|
|
|
34 |
1 |
p.
|
artikel
|
| 16 |
Perspectives on current survival and new developments in AML
|
Rowe, Jacob M.
|
|
|
34 |
1 |
p.
|
artikel
|
| 17 |
Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months
|
Flowers, Mary E.D.
|
|
|
34 |
1 |
p.
|
artikel
|
| 18 |
What are the molecular mechanisms driving the switch from MPNs to leukemia?
|
Wang, Xiaoli
|
|
|
34 |
1 |
p.
|
artikel
|
| 19 |
Which novel agents will have a clinically meaningful impact in AML at diagnosis?
|
Perl, Alexander E.
|
|
|
34 |
1 |
p.
|
artikel
|
| 20 |
Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making
|
Atallah, Ehab L.
|
|
|
34 |
1 |
p.
|
artikel
|
Tijdschrift beschrijving